ERBB2 and breast cancer: Of these, 24,188 (90.1%) were excluded: 24,103 (89.8%) non-Her2 positive BC, 69 (0.3%) primary metastatic (de novo) BC and 16 (0.1%) without surgical resection of the primary BC, leaving a total of 2654 women that comprised the study population.